Background-The cardiac sodium channel (SCN5A) mutation L1825P has been identified in a patient with drug-induced torsade de pointes precipitated by the I Kr blocker cisapride. Although L1825P generates late sodium current typical of SCN5A-linked long-QT syndrome (LQT3) in vitro, the patient reported had a normal QT interval before administration of the drug. To address this discrepancy, we tested the hypothesis that this mutant channel is not processed normally. Methods and Results-CHO cells transfected with L1825P displayed significantly reduced peak I Na (209Ϯ36 versus 23Ϯ3 pA/pF, PϽ0.05). Confocal imaging and cell-counting studies using epitope-tagged constructs demonstrated that cell surface expression of the mutant was only Ϸ9% of wild-type. Incubating transfected cells with cisapride partially rescued misprocessing to 30% of wild-type. As a result, "late" sodium current increased with cisapride from 1.2Ϯ0.11 to 5.04Ϯ0.77 pA/pF (PϽ0.05). Conclusions-L1825P fails to generate QT prolongation because it does not reach the cell surface. Moreover, the data suggest that cisapride caused torsade de pointes not only by blocking I Kr but also by rescuing cell surface expression of the mutant channel, further exaggerating the LQT3 phenotype. This not only represents a new mechanism in the drug-induced long-QT syndrome but also strongly supports the concept that variable cell surface expression contributes to clinical variability in the LQT3 phenotype. (Circulation. 2005;112:3239-3246.)
M utations in at least 8 genes have been reported as causes of the congenital long-QT syndrome (LQTS). [1] [2] [3] [4] SCN5A encodes the ␣-subunit of the cardiac-specific voltagegated sodium channel, and mutations in this gene have been linked to the LQT3 form of the disease. A common mechanism in LQT3 is impaired fast inactivation that leads to persistent "late" sodium current (I Na ), a phenotype referred as "gain of function." By contrast, other SCN5A-related arrhythmia syndromes, such as Brugada syndrome or conduction system disease, arise from reduced peak I Na caused by mutations that have been called "loss of function." One increasingly well-recognized mechanism underlying reduced sodium current in the Brugada syndrome and conduction disease is misprocessing of mutant channels, with retention in the endoplasmic reticulum (ER) and thus failure to reach the cell surface. [5] [6] [7] [8] 
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Although mutations in multiple genes can cause LQTS, the "acquired" form (aLQTS) is almost always a result of drug-induced block of the cardiac delayed rectifier potassium current I Kr . 9, 10 In some cases, development of the characteristic arrhythmia torsade de pointes after administration of an I Kr blocker has been the first clue to the diagnosis of subclinical congenital LQTS. [11] [12] [13] [14] Mutations in KCNQ1 (LQT1) and KCNH2 (LQT2), each encoding a component of delayed rectifier K ϩ current, are the most common causes of the congenital LQTS and have been reported in the acquired form as well. When such aLQTS-associated mutations are studied in vitro, the K ϩ current changes have been modest, an observation consistent with a near-normal baseline QT but enhanced risk for aLQTS. 11, 15 This is one example of a situation we have called "reduced repolarization reserve." 16 Three SCN5A mutations have been reported in aLQTS. [17] [18] [19] One, resulting in L1825P in the SCN5A C-terminus, was identified in a patient whose baseline ECG showed a normal QT interval and right bundle-branch block. 17 However, administration of the potent I Kr blocker cisapride provoked marked QT prolongation and torsade de pointes. Characterization of this mutant in a heterologous expression system demonstrated noninactivating late I Na typical of LQT3. The report also indicated that peak I Na was reduced compared with wild-type (WT). Accordingly, we hypothesized that this variant did not traffic normally to the cell surface, which might explain the lack of baseline QT interval prolongation. In the course of these studies, we also identified a new effect of the culprit drug, cisapride, to rescue L1825P misprocessing. Taken together, the data demonstrate for the first time a pharmacological rescue of a misprocessed LQT3 mutant as a disease mechanism in aLQT3 and thereby implicate variable cell surface expression as a modulator of the LQT3 phenotype.
Methods

Generation of Expression Vectors and Transient Transfection in CHO Cell Lines
The SCN5A DNA (Gen Bank accession No. NM000335), a gift from Dr Al George, was subcloned into the pBK-CMV vector (Stratagene). The L1825P construct was prepared using the QuickChange site-directed mutagenesis kit (Stratagene) according to the manufacturer's instructions. Recombinant PCR was used to introduce the FLAG (DYKDDDDK) epitope into the domain I extracellular S1-S2 linker in frame after nucleotide position 653, between Pro 153 and Pro 154. All constructs were sequenced to verify the desired mutation and epitope and to ensure the lack of other introduced variations.
Cultured Chinese hamster ovary (CHO) cells were transiently transfected with constructs described above using FuGENE6 (Roche Applied Science). A plasmid encoding the enhanced green fluorescent protein (pEGFP-N3, BD Bioscience Clontech) was cotransfected in electrophysiology experiments to identify transfected cells. Cells were grown for 48 hours after transfection before study. In drug rescue experiments, cisapride (Sigma-Aldrich Inc) was added to the culture media at concentrations ranging from 1 nmol/L to 1 mol/L, after which the cells were studied in cisapride-free conditions. For confocal microscopy imaging, cells were split 24 hours after transfection, transferred to a Laboratory-Tek II chamber slide system (Nalge Nunc International), and grown for another 24 hours.
Electrophysiology
Whole-cell voltage clamp was performed at room temperature with 2-M⍀ patch microelectrodes and an Axopatch 200A amplifier. The extracellular bath solution contained (in mmol/L) NaCl 145, KCl 4.0, MgCl 2 1.0, CaCl 2 1.8, glucose 10, and HEPES 10; the pH was 7.4, adjusted with NaOH. The pipette (intracellular) solution contained (in mmol/L) NaF 10, CsF 110, CsCl 20, EGTA 10, and HEPES 10; the pH was 7.4, adjusted with CsOH. Cells were held at Ϫ120 mV, and activating currents were elicited with depolarizing pulses from Ϫ100 to ϩ50 mV in 10-mV increments. Specific clamp protocols are indicated with the data. Late current was measured as the mean between 95 and 100 ms after the initiation of the depolarization. Data were acquired by use of pClamp8.0 (Axon Instruments Inc), sampled at 50 kHz, and low-pass filtered at 5 kHz. All currents were normalized to the cell capacitance calculated by Membrane Test (OUT O) in pClamp8.0.
Immunocytochemistry
Transfected CHO cells were washed with Tris-buffered saline (TBS, pH 7.4) twice and fixed with a freshly prepared mixture of methanol:acetone (1:1) for 1 minute. For surface staining, cells were incubated with mouse anti-FLAG M2 monoclonal antibody-FITC conjugate (1:300; Sigma-Aldrich Inc) in TBS with 2% BSA for 1 hour at room temperature, followed by extensive washing with TBS and mounting on glass coverslips.
To study intracellular localization, fixed cells were permeabilized and blocked with preincubation in 0.2% Triton X-100, 2% BSA, and 5% goat serum TBS at room temperature for 30 minutes. After the blocking solution had been washed out, cells were incubated with the same amount of the FITC-conjugated anti-FLAG antibody as described above for 1 hour. After being washed, these cells underwent ER staining with a primary rabbit polyclonal antibody to calnexin (1:200; Novus Biologicals Inc) and a secondary goat polyclonal antibody to rabbit IgG conjugated with Cy3 (1:200; Novus Biologicals Inc) 5, 6 ; there was a 1-hour incubation period in each step followed by a wash.
Fluorescent probe-labeled cells were examined using a Zeiss LSM510 confocal laser-scanning inverted microscope (Carl Zeiss) equipped with an argon-krypton laser beam. A 63ϫ1.4 planapochromat oil objective lens with a 1.5 numerical aperture was used. FITC and Cy3 fluorophores were excited at of 488 and 543 nm at 50% laser power with detector gain set to 900. Fluorescence was filtered by BP505-550 and LP560 filters, respectively.
Immunoblot Analysis
Whole-cell lysates were collected 48 hours after transfection with FLAG-tagged WT or L1825P constructs as previously described. 20 The same amount of protein extract (20 g each for controls, WT, or L1825P) was loaded into 4% to 12% precast NuPAGE gels (Invitrogen Corp) and then separated by SDS-PAGE under reducing conditions. After electrophoresis, proteins were transferred to a Hybond polyvinylidine difluoride membrane (Amersham Biosciences Corp), blocked with 5% nonfat milk in TBS-T (TBS with 0.05% TWEEN-20) at room temperature for 1 hour, and incubated with horseradish peroxidase-conjugated anti-FLAG M2 monoclonal antibody (1:300; Sigma) in TBS-T at room temperature for 1 hour. After an intensive wash with TBS-T, the immunoreaction between the antibody and the FLAG antigen of the tagged channel was visualized using the ECL system (Amersham Bioscience Corp).
Flow Cytometry and Quantification of Cell Surface Expression
Transfected CHO cells were harvested by incubation with PBS, pH 7.4, containing 0.5 mmol/L EDTA for 10 minutes at room temperature, followed by 2 washes with TBS. Cell surface staining was performed as described above using FITC-conjugated anti-FLAG M2 antibody. After an extensive washing step, the cells were examined for FITC-labeled, FLAG-tagged channel expression by fluorescence-activated cell sorting (FACS) on a FACSCalibur bench-top analyzer (BD Bioscience), using CellQuest (BD Bioscience) for data acquisition and analysis. FLAG-tagged channel expression was quantified by converting the geometric mean fluorescence intensity from each cell preparation to the number of Figure 1 . Effects of the L1825P mutation on sodium current. A, Whole-cell Na ϩ current (I Na ) from CHO cells expressing WT SCN5A or L1825P. Representative traces were recorded with test potentials of 100-ms duration from Ϫ100 to ϩ50 mV in 10-mV increments and from a holding potential of Ϫ120 mV. B, Example of late I Na for WT and L1825P elicited by a test depolarization pulse from Ϫ120 mV to Ϫ20 mV for 100 ms. Late I Na was measured as the mean between 95 and 100 ms after the initiation of the depolarization, normalized to cell surface, and presented in pA/pF. molecules of equivalent soluble fluorochromes (MESF) using the fluorescence quantification kit (Bangs Laboratories Inc). The MESF value obtained from the control samples, ie, the cells transfected with the empty vector (pBK-CMV), was subtracted as a background from each test sample. The relative surface expression level of L1825P mutant was determined by dividing its MESF values by that of the WT channel. 21 
Luo-Rudy Simulation
Simulations were conducted using the single-cell formalism of the theoretical dynamic model of a mammalian ventricular action potential (Luo-Rudy model). 22, 23 The transient inward potassium current, I To , was introduced into the Luo-Rudy model as described previously. 24 To examine the effect of L1825P mutation, the biophysical consequences of the mutation were introduced into the formalism of the sodium channel. Briefly, peak inward current was reduced by a factor of 10 to reflect the lower expression of L1825P, the voltage dependence of activation (represented by the m gate) was shifted by ϩ9 mV, and the steady-state inactivation (represented by the h and j gates) was shifted by Ϫ11 mV. 17 The sustained inward component of current (as observed in LQT3 mutant channels) was simulated as described earlier. 25 Slowing of inactivation was simulated by increasing the time constant of inactivation by a factor of 1.5. For action potential simulations, a heterozygous condition (50/50 mixture of mutant and WT channels) was assumed to reflect equal penetrance. The effect of cisapride was simulated by decreasing the conductance of I Kr by 85%, whereas for the rescue of L1825P by cisapride, L1825P current was scaled to 30% of WT without affecting other gating parameters.
Statistical Analysis
Data are expressed as meanϮSD (standard deviation of the mean). Statistical significance was determined using the Student t test for comparisons of 2 means or using ANOVA for comparisons of multiple means. Differences were considered statistically significant with a probability value of PϽ0.05. Figure 1A shows sodium currents recorded from CHO cells expressing WT or L1825P channels. Fewer GFP-positive L1825P cells actually displayed any current (9 of 12 for WT versus 11 of 40 for L1825P, PϽ0.05). Furthermore, peak L1825P current was greatly reduced compared with WT (WT, 209Ϯ36 pA/pF, nϭ9; L1825P, 23Ϯ3 pA/pF, nϭ11; PϽ0.05). Finally, despite the reduction in peak current and in line with the previous report, 17 a robust noninactivating (late) I Na , as shown in Figure 1B , was obtained with L1825P (WT, 0.48Ϯ0.1 pA/pF, nϭ9; L1825P, 1.2Ϯ0.11 pA/pF, nϭ11; PϽ0.05).
Results
L1825P Generates Reduced Peak Current
Reduced Cell Surface Expression of L1825P
One obvious explanation for these results is that L1825P might not be processed correctly, as has been reported for a number of Brugada syndrome mutations. [5] [6] [7] [8] 26, 27 To test this idea, an extracellular FLAG epitope was introduced into both WT and L1825P channels and their cellular localization studied. Figure 2A shows staining in nonpermeabilized cells with the FITC-conjugated anti-FLAG antibody. Staining in WT-transfected cells indicates that the WT-FLAG channels are localized to the plasma membrane. By contrast, little staining was observed on the surface of the cells transfected with L1825P-FLAG. Quantification of cell surface expression by FACS and MESF ( Figure 2B ) in Ͼ15 000 cells in 3 separate experiments revealed a 91% reduction of the L1825P mutant (MESF values: WT, 329 812Ϯ2320, nϭ3; L1825P, 30 136Ϯ2086, nϭ3, PϽ0.05). Western blots of whole-cell extracts (Figure 2C) showed comparable protein levels for WT and L1825P, indicating that the L1825P channel protein was synthesized but did not reach the cell surface. Further support for this idea is presented in Figure 2D , showing that in permeabilized cells, the staining pattern of the L1825P channel overlapped nearly completely with that of the ER-resident protein calnexin, in contrast to the cell surface expression seen clearly in the parallel WT experiment.
Mutant Cell Surface Expression Is Partially Rescued by Cisapride
Misprocessing of mutant cell surface proteins is an increasingly well-recognized mechanism underlying loss-offunction phenotypes in diseases like the congenital long-QT syndromes, the Brugada syndrome, and cystic fibrosis. 5-8,26 -30 In these settings, ER retention of presumably misfolded proteins has been rescued by incubation with a range of small-molecule and other interventions. 8,28,30 -34 Accordingly, we evaluated the effects of incubation with cisapride, the culprit drug in torsade de pointes in the L1825P mutation carrier. Figure 3A shows that the presence of cisapride in the culture media for 48 hours had no effect on WT I Na but increased peak I Na of the L1825P mutant in a concentration-dependent manner (from 1 nmol/L to 1 mol/L), as summarized in Figure 3B . The same results were obtained when the study was repeated in tsA-201 cells, in which the mutant was originally characterized. The effect of cisapride was studied further by confocal imaging as above; Figure 3C shows that culturing the L1825P channel with 1 mol/L cisapride resulted in greater surface immunostaining compared with L1825P alone; quantification demonstrated a 3-fold enhancement of expression in MESF values (L1825Pϩ . Cisapride facilitates L1825P channel membrane expression in a dosedependent manner. A, Current traces for WT and L1825P recorded after 48 hours of cell culture with a range of concentrations of cisapride. B, Summary data of peak I Na densities from WT and L1825P without or with cisapride at the indicated concentration during cell culture. Peak I Na was elicited at Ϫ20 mV from a holding potential of Ϫ120 mV and normalized to cell capacitance and presented as pA/pF. When cells expressing L1825P were studied, only those that generated detectable I Na were counted; the majority (Ͼ75%) generated no I Na . C, Immunostaining (anti-FLAG, green) of L1825P-FLAG-transfected cells. Top, Rescued surface labeling when incubated with 1 mol/L cisapride for 48 hours. Bottom, FACS analysis as in Figure 2B . Cell surface expression with cisapride culture was increased 3-fold compared with no cisapride conditions. cisapride, 100Ϯ4070, nϭ3, PϽ0.05). Although this effect might be expected to "rescue" a Brugada syndrome phenotype, it may also increase late current and thus worsen the LQT3 phenotype. Indeed, late current increased in proportion to peak current (Figure 4 : L1825P, 1.2Ϯ0.11 pA/pF, nϭ11; L1825Pϩcisapride, 5.04Ϯ0.77 pA/pF, nϭ8; PϽ0.05), as would be expected with rescue of cell surface expression.
Cisapride Has No Gating Effect on Either WT or L1825P Channel
Previous studies showed that acute cisapride exposure did not change the kinetics of the I Na in either WT or L1825P. In this study, however, we determined the effects of longer exposure to the drug. Figure 5 shows that this longer cisapride exposure did not alter WT or L1825P gating; the differences between the 2 channels in time constants and in voltage dependence of inactivation are those previously reported. 17 Figure 6 shows the results of action potential reconstructions using the Luo-Rudy model under 4 different conditions: WT; mutant (50% WT and 50% L1825 channels, modeled using late currents from Figure 4) ; mutant with superimposed I Kr block (the recognized cisapride effect 35 ); and mutant with superimposed I Kr blockϩL1825P rescue. Incorporating the mutant produces minimal action potential prolongation. The simulation with I Kr blockϩmutant channels rescued by cisapride shows the longest action potentials and is the only one with an early afterdepolarization. This finding highlights the new mechanism we have identified as a contributor to drug-induced arrhythmia in this setting: action potential prolongation caused by I Kr block by cisapride is exaggerated by rescue of misprocessed mutant channels. Figure 5 . Chronic cisapride exposure does not alter gating of WT or L1825P channels. A, Slow (top) and fast (bottom) time constants for fast inactivation. These parameters were obtained by fitting the biexponential function I/I max ϭA 0 ϩA 1ϫ exp(Ϫt/ 1 )ϩA 2ϫ exp(Ϫt/ 2 ) to fast inactivation, where A i are amplitude terms and i are time constants. All data in this figure are coded as follows: WT (Ⅲ), L1825P (•), WT with cisapride exposure for 48 hours as described in the text ('), and L1825P with cisapride ('); nՆ9 for all data shown here. B, Sodium channel availability and steady-state activation were obtained by using the pulse protocols shown in the inset. Curves were fit with a Boltzmann distribution to determine the voltage midpoint (V 1/2 ) and slope factor (k). A hyperpolarizing shift of steady-state inactivation in L1825P was identified (V 1/2 : WT, Ϫ97.0Ϯ1.4 mV, nϭ9; L1825P, Ϫ104.3Ϯ1.5 mV, nϭ12; PϽ0.05), with a larger slope factor (k: WT, 7.84Ϯ0.39 mV; L1825P, 9.65Ϯ0.45 mV; PϽ0.05). Cisapride did not affect this shift (V 1/2 : WT-Cisa, Ϫ98.4Ϯ1.4 mV, nϭ9; L1825P-Cisa, Ϫ105.0Ϯ1.48 mV, nϭ11). C, Development of inactivation was measured using the 2-pulse protocol shown in the inset, and the fractional current (P2/P1) was plotted against the logarithm of P1 prepulse duration. The curves were fit with a single exponential equation, and no effect of cisapride preexposure was observed. D, Time course of recovery from inactivation was studied using the 2-pulse protocol shown in the inset and analyzed by fitting data to biexponentials: I/I max ϭA 1ϫ [1Ϫexp(Ϫt/ 1 )]ϩA 2ϫ [1Ϫexp(Ϫt/ 2 )]. There was no difference in the time constants for recovery from inactivation: 1 (WT, 4.7Ϯ0.19 ms, nϭ9; L1825P, 4.6Ϯ0.22 ms, nϭ12; PϾ0.05) and 2 (WT, 105.3Ϯ8.7 ms, nϭ9; L1825P, 106Ϯ9.2 ms, nϭ12; PϾ0.05). The slow fraction was larger with L1825P (WT, 0.09Ϯ0.02; L1825P, 0.125Ϯ0.02; PϽ0.05), as previously reported, 17 and addition of cisapride to the cell culture had no effect: 1 (WT, 4.76Ϯ0.2 ms; L1825P, 4.6Ϯ0.21 ms); 2 (WT, 116Ϯ14.4 ms; L1825P, 103.9Ϯ13.9 ms); the slow fraction (WT, 0.1Ϯ0.02; L1825P, 0.127Ϯ0.02).
Prolonged Action Potential Duration by Cisapride in Simulation
Discussion
Acquired LQTS occurs in up to 8% of patients treated with certain antiarrhythmics, and much less commonly with a wide range of "noncardiovascular" drugs, including certain antibiotics, antipsychotics, antihistamines, and the prokinetic gastrointestinal agent cisapride. 19 For virtually all culprit drugs, which share few structural features, block of the repolarizing current I Kr is the mechanism underlying action potential prolongation. In a minority of cases, the acquired form of the disease is the first manifestation of subclinical congenital long-QT syndrome. [11] [12] [13] [14] In this study, we found that L1825P, previously identified and characterized as a subclinical LQT3 mutation discovered by challenge with the potent I Kr blocker cisapride, is not processed normally to the cell surface. Such misprocessing is an increasingly well-recognized mechanism in diseases such as Brugada syndrome, 5, 6, 8 diabetes insipidus, 34, 36 or cystic fibrosis involving membrane proteins, 29 and is well described in common forms of LQTSlinked loss-of-function mutations in potassium channel genes. 20, 28 However, this mechanism has been reported in only 1 case of the congenital LQT3 caused by gain-offunction mutations in the cardiac sodium channel gene SCN5A. 30 Furthermore, we also observed an unexpected dose-dependent effect of cisapride to rescue in cytoplasmic misprocessing of the L1825P channel.
Initial studies of this variant revealed a spectrum of gating defects typically seen in other LQT3 mutants, including a prominent late (noninactivating) plateau inward current underlying QT prolongation. Thus, L1825P would be predicted to generate QT prolongation in the baseline ECG in mutation carriers; however, this was not observed in the reported proband. Such dissociation be-tween genotypes and clinical phenotypes is increasingly well recognized in LQTS, and the studies we performed suggest a novel mechanism in LQT3: we find that L1825P is retained in the ER, and its forward trafficking to the plasma membrane is enhanced by chronic treatment of the I Kr blocker cisapride, as opposed to the null effect after the acute exposure in the original report. 17 Consequently, we postulate that with cisapride challenge, L1825P mutants retained in the ER were transported to the cell surface; however, in this case, this restored membrane integration contributed to an increased QT-prolonging defect attributable to increased persistent late I Na . Thus, in this case, cisapride prolonged QT not only by blocking I Kr but also by exacerbating the LQT3 phenotype.
Trafficking-defective SCN5A mutations have been reported in patients with loss-of-function in vitro phenotypes associated with SCN5A-related congenital arrhythmia syndromes. [5] [6] [7] [8] 30 Although disruption of surface expression is the common feature for these variants, the nature of the clinical symptom did not always correlate with the reported in vitro characteristics. Trafficking mutation carriers of G1743R, R1432G, and R1232W/T1620M displayed Brugada arrhythmias with right precordial ST-segment elevation 5, 6, 8 ; this phenotype was absent in the conduction disorder caused by a similar trafficking defect of a frameshift truncated protein (5280delG). 7 In addition, a congenital LQT3 mutation (M1766L) discovered in a symptomatic newborn was also determined to exhibit defective processing to the cell surface. 30 Cell surface expression of both M1766L and G1743R has been reported to be rescued by mexiletine, a Na ϩ channel blocker sometimes used in the treatment of LQT3. 8, 30 Peak I Na of M1766L and G1743R were increased 12-and 93-fold, respectively, when cultured with a very high concentration (500 mol/L) of mexiletine, well above the therapeutic range of 2.8 to 11 mol/L. 37 Similarly, we have found that high concentrations of quinidine and lidocaine can rescue L1825P (data not shown). 38 Indeed, a common emerging theme is rescue of misprocessed mutant cell surface molecules by pharmacological agents known to bind to these molecules. 8,28,30 -34 The initial studies on KCNH2 mutant N470D illustrated that blockers including E-4031, astemizole, and cisapride can restore the trafficking of the mutant proteins, possibly by acting as chemical chaperones to promote proper protein folding or assembly, thereby permitting the channel to exit the ER. 28 Our study shows for the first time that surface expression of a trafficking defect LQT3 mutation can be rescued by the I Kr blocker cisapride at close to its therapeutic concentration of 0.17 mol/L. 39 The mechanism underlying the cisapride effect is uncertain; although it may behave as a chaperone, this effect could also reflect nonspecific actions on the general ER quality control apparatus.
This study, like previous work in the field, examined membrane proteins in heterologous expression systems. A limitation of this approach is that cardiac myocytes could include regulatory mechanisms absent in CHO or tsA-201 cells and thus exhibit a different phenotype. A challenge to the field is to develop systems to study mutant membrane Figure 6 . The effect of L1825P mutation on action potentials using the Luo-Rudy model. A heterozygous formulation of sodium channels (50% WT and 50% mutant) has a minimal effect on action potential duration (blue). In the presence of an I Kr blocker (cisapride), there is significant action potential prolongation (green). Incorporation of rescue of sodium channels because of cisapride (red) augments action potential prolongation and causes an early afterdepolarization, indicated by the arrow.
proteins in more physiological contexts, ie, with normal numbers, under normal transcriptional control, in native cells.
In conclusion, our study demonstrates SCN5A L1825P to be an ER-retained LQT3 mutation, and its cell surface expression can be partially restored by cisapride close to the therapeutic concentration. However, by augmenting late inward sodium current, this rescue probably exacerbated the LQT3 phenotype. These data not only identify a new mechanism contributing to the acquired LQTS phenotype but also strongly support the concept that the well-recognized phenotypic variability in LQTS and other diseases of cell surface molecules may be determined in part by variable delivery of channels to the cell surface.
